< Back

Foundayo

MED-000028

Foundayo (orforglipron) is Eli Lilly's once-daily oral GLP-1 medication for chronic weight management, approved April 1, 2026, and the first small-molecule, non-peptide GLP-1 receptor agonist, meaning it can be taken at any time of day without food or water restrictions, unlike the Ozempic and Wegovy tablets.

Medication Overview

Generic Name:

Medication Class:

Manufacturer:

Route:

Dosing Frequency:

Orforglipron

GLP-1 (non-peptide, small molecule)

Eli Lilly

Oral tablet

Daily

Status:

Draft

Medication Summary

Aliases

Orforglipron

Search Keywords

foundayo, orforglipron, foundayo weight loss, foundayo pill, oral glp-1 pill lilly

Medication Uses

Part of the DietApp.com GLP-1 Medication Database, a comprehensive, regularly reviewed reference covering every GLP-1-class medication.

Foundayo (orforglipron) is an FDA-approved oral GLP-1 receptor agonist indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction in adults with obesity, or adults who are overweight with at least one weight-related condition such as hypertension or obstructive sleep apnea. It is Eli Lilly's second FDA-approved obesity medicine, approved April 1, 2026.

Foundayo is a small-molecule, non-peptide GLP-1 receptor agonist, a genuinely different chemical category from every other GLP-1 medication in this library, all of which are peptide-based. It is not approved for type 1 diabetes, and safety and effectiveness in children haven't been established.

Dosage

Dosing is determined by your prescribing provider and follows a gradual titration schedule, starting at a lower dose and increasing over several weeks to reduce gastrointestinal side effects, consistent with the general approach used across GLP-1 medications. Specific dose strengths and titration steps are set by your provider based on your individual response and tolerability.

Administration

Foundayo is taken once daily, and its most distinctive practical feature is that it can be taken at any time of day, with or without food, and without water restrictions. This is a meaningful difference from the Ozempic and Wegovy tablets, which are peptide-based and require strict empty-stomach, minimal-water, 30-minutes-before-food administration. Foundayo's small-molecule structure doesn't require that same absorption protocol.

Benefits

In the 72-week ATTAIN-1 clinical trial, adults taking Foundayo lost an average of 27 pounds at the highest studied dose. Beyond the weight-loss result itself, Foundayo's core practical benefit is accessibility: as a small molecule, it's easier to manufacture at scale than peptide-based GLP-1 medications, and its lack of dosing-ritual requirements may make it a more convenient option for people who find the administration rules of other oral GLP-1s difficult to follow consistently.

Side Effects

The most common side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, abdominal swelling, fatigue, belching, heartburn, gas, and hair loss. In the ATTAIN-1 trial, nausea occurred in roughly 30 to 40% of participants at the highest dose, with vomiting and diarrhea each occurring in a similar range, most cases mild to moderate and concentrated in the first eight weeks during dose titration.

Warnings

Foundayo carries the same FDA boxed warning as other GLP-1 medications in this library, regarding the risk of thyroid C-cell tumors, including thyroid cancer, observed in rodent studies. Watch for a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath, and tell your provider immediately if any of these occur. Use of Foundayo alongside another GLP-1 receptor agonist medication is not recommended.

A specific warning worth knowing: there is no legal compounded version of Foundayo. Because orforglipron is a small-molecule compound, not a peptide, it cannot legally be compounded the way semaglutide or tirzepatide sometimes can under narrow exceptions. Any website selling "compounded orforglipron" is offering either an outright fraudulent product or an unapproved research chemical, not a legitimate medication. The only legitimate source is Eli Lilly, through a licensed pharmacy prescription or LillyDirect.

Drug Interactions

Foundayo has documented interactions worth discussing with your provider, including with CYP3A4-metabolized medications and simvastatin specifically. As with other GLP-1 medications, it may also affect the absorption of other oral medications due to its effects on gastric motility, though this is generally considered less pronounced than with the peptide-based oral tablets given Foundayo's different mechanism.

Storage

Store Foundayo tablets according to the manufacturer's specific instructions provided with your prescription. As an oral tablet rather than an injectable, it does not require refrigeration the way injectable GLP-1 pens do. Keep out of reach of children.

References

Eli Lilly and Company: FDA Approves Foundayo (orforglipron) Press Release, April 1, 2026
Drugs.com: Foundayo (orforglipron) FDA Approval History
Medical News Today: A Detailed Guide to Foundayo

Last medically reviewed and updated: July 11, 2026.

Track Your Progress

Whether you're taking Foundayo, another oral GLP-1, or an injectable, DietApp.com helps you track your dose, nutrition, weight, and symptoms in one place.

Related Resources

Semaglutide Medication Guide
Tirzepatide Medication Guide
Does Medicare Cover GLP-1 Medications?

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Explore DietApp.com Tools

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.